VCYT Q3 2025 Earnings — Veracyte, Inc. Revenue & Financial Results | Market Cap Arena

VCYTVeracyte, Inc.

$3B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$132M+13.8% YoY

Gross Profit

$91M69.2% margin

Operating Income

$23M17.4% margin

Net Income

$19M14.5% margin

EPS (Diluted)

$0.24

QoQ Revenue Growth

+1.3%

Cash Flow

Operating Cash Flow

$45M

Free Cash Flow

$42M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$110M

Stockholders' Equity

$1.3B

Cash & Equivalents

$316M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$132M	$116M	+13.8%
Gross Profit	$91M	$79M	+15.5%
Operating Income	$23M	$12M	+90.9%
Net Income	$19M	$15M	+26.3%

Revenue Segments

Testing

$128M97%

Product

$3M2%

Biopharmaceutical And Other

$1M1%